Literature DB >> 17178385

Optimisation of the sensitisation conditions for an ovalbumin challenge model of asthma.

Nicola Smith1, Kenneth J Broadley.   

Abstract

Antigen inhalation in patients with atopic asthma results in an early asthmatic response (EAR), accompanied by a late asthmatic response (LAR) in 60% of patients, airway hyperresponsiveness (AHR) and inflammatory cell infiltration to the lungs. An ideal animal model of asthma should, therefore, provide at least these 4 features consistently and reproducibly. The aim of this study was to optimise the ovalbumin (OA) sensitisation conditions, for achieving EAR, LAR, AHR and cell influx, in a guinea-pig model of asthma. Animals were sensitised with 10 micro g or 100 micro g OA, as either a single or booster (day 1 and day 5) injection. Airway responses to inhaled OA (10 micro g, 1 h) of actively sensitised, conscious guinea pigs were determined by whole body plethysmography as the change in specific airways conductance (sG(aw)) over a 12 h period and at 24 h. Bronchoconstriction by inhaled histamine (1 mM) was used to investigate AHR, and inflammatory cell influx was determined by bronchoalveolar lavage (BAL), both at 24 h post-challenge. A single sensitisation with 10 micro g OA did not reveal an EAR, LAR or AHR following exposure to OA. However, total and differential cell counts (eosinophils and macrophages) were significantly greater 24 h post-challenge, when compared to saline-challenged sensitised animals. The addition of a booster injection of 10 micro g revealed an EAR, but no LAR or AHR after ovalbumin inhalation. However, there was a significant cell influx. Sensitisation with 100 micro g OA (single and booster injections) revealed all four parameters of the asthmatic response (EAR, LAR, AHR and cell influx). The incorporation of the booster sensitisation injection resulted in a prolongation of the LAR, and the AHR was more pronounced and cell influx increased significantly, when compared to all other sensitisation protocols. Thus, sensitisation with 100 micro g OA (with a booster injection) can reveal an EAR, LAR, AHR and cell influx following inhalation exposure to OA (10 micro g). Cellular infiltration to the lung may be a poor marker of the asthmatic response, as a threshold level of cell influx (eosinophils) appears to be required in order to elicit the LAR and AHR. There was an association between the LAR and AHR.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17178385     DOI: 10.1016/j.intimp.2006.09.007

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  7 in total

1.  The effect of liposome encapsulation on the pharmacokinetics of recombinant secretory leukocyte protease inhibitor (rSLPI) therapy after local delivery to a guinea pig asthma model.

Authors:  Aileen Gibbons; Danielle Padilla-Carlin; Ciara Kelly; Anthony J Hickey; Clifford Taggart; Noel G McElvaney; Sally-Ann Cryan
Journal:  Pharm Res       Date:  2011-06-07       Impact factor: 4.200

2.  Discovery of MK-8318, a Potent and Selective CRTh2 Receptor Antagonist for the Treatment of Asthma.

Authors:  Xianhai Huang; Jason Brubaker; Wei Zhou; Purakkattle J Biju; Li Xiao; Ning Shao; Ying Huang; Li Dong; Zhidan Liu; Rema Bitar; Alexei Buevich; Joon Jung; Scott L Peterson; John W Butcher; Joshua Close; Michelle Martinez; Rachel N MacCoss; Hongjun Zhang; Scott Crawford; Kevin D McCormick; Robert Aslanian; Ravi Nargund; Craig Correll; Francois Gervais; Hongchen Qiu; Xiaoxin Yang; Charles Garlisi; Diane Rindgen; Kevin M Maloney; Phieng Siliphaivanh; Anandan Palani
Journal:  ACS Med Chem Lett       Date:  2018-06-23       Impact factor: 4.345

3.  Bronchoprotection in conscious guinea pigs by budesonide and the NO-donating analogue, TPI 1020, alone and combined with tiotropium or formoterol.

Authors:  D l Turner; N Ferrari; W R Ford; E J Kidd; B Nevin; L Paquet; P Renzi; K J Broadley
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

4.  Antigen-induced airway hyperresponsiveness and obstruction is related to caveolin-1 expression in airway smooth muscle in a guinea pig asthma model.

Authors:  Mayra Álvarez-Santos; Patricia Ramos-Ramírez; Fernando Gutiérrez-Aguilar; Sandra Sánchez-Hernández; Ricardo Lascurain; Raúl Olmos-Zuñiga; Rogelio Jasso-Victoria; Norma A Bobadilla; Blanca Bazan-Perkins
Journal:  Clin Transl Allergy       Date:  2015-03-26       Impact factor: 5.871

5.  LPS exacerbates functional and inflammatory responses to ovalbumin and decreases sensitivity to inhaled fluticasone propionate in a guinea pig model of asthma.

Authors:  A P P Lowe; R S Thomas; A T Nials; E J Kidd; K J Broadley; W R Ford
Journal:  Br J Pharmacol       Date:  2015-03-24       Impact factor: 8.739

6.  Adjustment of sensitisation and challenge protocols restores functional and inflammatory responses to ovalbumin in guinea-pigs.

Authors:  Alexander P P Lowe; Kenneth J Broadley; Anthony T Nials; William R Ford; Emma J Kidd
Journal:  J Pharmacol Toxicol Methods       Date:  2014-10-30       Impact factor: 1.950

7.  Interleukin‑27 ameliorates allergic asthma by alleviating the lung Th2 inflammatory environment.

Authors:  Jiameng Lu; Xiaoqing Ji; Lixia Wang; Fei Sun; Chuanjun Huang; Haiying Peng; Yunxiu Jiang; Zihan Guo; Xinyi Liu; Yanbo Ji; Degan Lu
Journal:  Int J Mol Med       Date:  2022-05-06       Impact factor: 5.314

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.